Best Growth Stocks to Buy for October 28th

Zacks highlighted Eni, Five Below and Oscar Health as Rank #1 stocks, citing current-year earnings consensus estimates that rose over the prior 60 days by 13%, 14.7% and 18.8%, respectively. The article presents them as growth-stock ideas but provides no earnings results or market reaction.

Analysis

The estimate revisions are a momentum screen, not evidence that earnings quality or forward cash flow has improved. Without the underlying forecast changes, valuation, and drivers, there is no robust basis to buy all three.

For Eni, estimate momentum is most vulnerable to reversal if oil and gas prices weaken or currency and refining effects offset upstream strength. Integrated operations can cushion commodity swings, so a cleaner read is cash flow and capital returns across a commodity move—not the earnings estimate alone. Over 1–3 months, watch commodity prices and guidance; over 6–18 months, energy-transition investment and execution can widen the gap between accounting earnings and distributable cash.

For FIVE, the key second-order question is whether value-seeking shoppers support traffic without deeper promotions eroding gross margin. A revision-driven rerating would be fragile if comparable sales improve only through discounting or if inventory and shrink worsen. Dollar-store competitors could also intensify price pressure.

For OSCR, forecast upgrades are particularly exposed to medical-cost trends, member mix, and ACA policy and reimbursement changes. A better top-line outlook is not enough if utilization or risk-adjustment economics deteriorate. Policy and rate-setting are medium-term catalysts; medical-cost data can change the near-term setup quickly.

Contrarian read: treating three unrelated estimate revisions as a common “growth” signal overlooks very different drivers and downside asymmetries. The article supplies no valuation, forecast detail, or fundamental confirmation; avoid an indiscriminate basket trade.

Key Decisions for Investors

• No immediate basket purchase. Before acting, verify the magnitude and source of each estimate revision, current valuation, and whether revisions reflect recurring operations rather than commodity assumptions, promotional sales, or favorable medical-cost timing.
• E: keep on a conditional watchlist rather than chase. Consider exposure only if cash-flow and capital-return guidance hold through weaker commodity prices; a sustained decline in oil and gas prices or a cut to cash-return plans would invalidate the positive revision signal.
• FIVE: wait for comparable-sales and gross-margin evidence. Upgrade the view if traffic and sales gains coexist with stable margins; avoid or reduce exposure if promotions deepen, inventory builds, or shrink pressures worsen.
• OSCR: require confirmation in medical-cost trends and policy-sensitive guidance before adding. Reassess promptly on adverse utilization, risk-adjustment, or reimbursement signals; those could overwhelm improved estimates.